Granules India

Value: integrated API-formulations

Last close: ₹866.75; 29 Sept 2026 · reference
1D · 1M: +1.8% · +3.6%; price-only
Weight: 0.7%; 31 Jul 2026 · Aug rank —
Thesis review: 8 Sep 2026; Why We Own, p44

Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗

Broker research

No sell-side reports on file

UnavailableUpload broker PDFs to data/research/broker/pdf and run the extraction to add them here.

SWOT

Strengths · Weaknesses · Opportunities · Threats

Draft

Strengths

Mix shift is real: complex generics 50% of FD (vs 39%), gross margin 65.6% and EBITDA margin 22.95% in Q1FY27 vs 20% a year ago; consensus expects 23% p.a. earnings growth.
Diversifying away from the US (72% of revenue): Europe +51% and RoW +56% YoY in Q1FY27 with a new EU-GMP certificate for Genome Valley.
Balance sheet fixed: net debt Rs 101 cr (0.07x EBITDA, from 0.34x at FY26), OCF Rs 387 cr in one quarter, ROCE 18%.
Pipeline: 25 ANDAs pending (USD 40 bn addressable brand value), second sole FTF (sodium oxybate ER, USD 267 mn brand); GPI Chantilly cleared with VAI in Apr-2026.

Weaknesses

vs Divi's Laboratories: Divi's trades at a far higher multiple for its API/CDMO franchise; Granules at ~21x FY28E offers 30% EPS CAGR with its own (smaller) peptide CDMO option via Senn.
vs Laurus Labs: Laurus's earnings depend on lumpy CDMO/ARV cycles and it carries more leverage; Granules is near net-debt-free (0.07x) with 23% EBITDA margins on a steadier finished-dosage base.

Opportunities

USFDA re-inspection and closure of the Gagillapur warning letter (timing unannounced as of Jul-2026).
Sodium oxybate ER (sole FTF) approval/launch and further complex generic approvals from the 25 pending ANDAs.
Senn peptide CDMO scale-up toward USD 50 mn revenue; Q2FY27 results (Nov-2026) to confirm 23%+ margins.

Threats

Gagillapur (Hyderabad) USFDA warning letter (issued 26-Feb-2025) remains active pending re-inspection; 7 of 8 sites have clean EIRs but no re-inspection date (Jul-2026).
Concentration: North America 72% of revenue and paracetamol/metformin-type molecules exposed to US price erosion and 26% reciprocal-tariff risk flagged by analysts.
Management stepped back from its 24-25% EBITDA margin guidance in Q1FY27; promoter holding only 38% and down ~4pp over 3 years.

Compiled from the approved one-pager (Why We Own What We Own, 8 Sep 2026): why-we-own → strengths, catalysts → opportunities, key risks → threats, peer caveats → weaknesses. Editorial mapping pending review. · author: compiled from the approved one-pager

Research reports · upload with a check step

0 approved · 0 pending · 0 rejected

Only approved reports are readable from the company page; the reviewer must differ from the uploader. Files are hashed (duplicates skipped) and held in the private store.

Internal evidence

Buoyant sources for this name

August 2026 top-30 disclosure — rank n/a, HealthCare, —. Buoyant AIF I Top 30 Holdings - Aug 2026.pdf
One-pager, "Why We Own What We Own" — p44, 8 Sep 2026. Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026)
Sales playbook, Aug 2026 — holdings matrix (PMS/AIF I/AIF II, $31 Jul 2026). Buoyant_Capital_Sales_Playbook_Aug_2026_Full_Holdings.pdf

Original PDFs are in the supplied package on disk; private object storage is not configured, so source pages are referenced, not served.

Company filings

Investor documents (Tijori knowledge base)

annual reports

earnings releases

investor presentations

conference calls

Links open the issuer's or exchange's document; fetched only through the user's browser, never by the platform.

Ownership

Shareholding · Jun'26

Promoter	38.02%
Indian Promoters	37.67%
KRISHNA PRASAD CHIGURUPATI	31.00%
CHIGURUPATI UMA DEVI	3.73%
TYCHE INVESTMENTS PRIVATE LIMITED	1.43%
PRAGNYA CHIGURUPATI	0.74%
CHIGURUPATI PRIYANKA	0.73%
SUSEELA DEVI CHIGURUPATI	0.03%
NIKHILA REDDY YEDAGURI	0.01%
KALIDINDI ABINAV VARMA	0.00%
VENKATA MAHESH KRISHNA NARRA	0.00%
HARSHA CHIGURUPATI	0.00%
Foreign Promoters	0.34%
SANTHI SREE RAMANAVARAPU	0.34%